Academic Journal
Evaluating contributions of neuropsychological, psychiatric, and inflammatory processes to the expression of cognitive symptoms in post-acute COVID-19 syndrome.
| Τίτλος: | Evaluating contributions of neuropsychological, psychiatric, and inflammatory processes to the expression of cognitive symptoms in post-acute COVID-19 syndrome. |
|---|---|
| Συγγραφείς: | Watson, Luke S., Toubouti, Youssef, Gray, Sarah M., Guillén, Núria, Pérez-Millan, Agnès, Rami, Lorena, Sanchez-Valle, Raquel, Johannesen, Jason K. |
| Πηγή: | Frontiers in Psychiatry; 2/19/2026, p1-13, 13p |
| Θεματικοί όροι: | Neuropsychological tests, Cognition disorders, Mental illness, Cytokines, Post-acute COVID-19 syndrome, Regression analysis, Mental fatigue |
| Περίληψη: | Introduction: Post-acute COVID-19 syndrome (PACS) has been widely associated with cognitive symptoms, however, the nature and severity of effects on cognitive function have been difficult to establish amid other aspects of PACS symptomatology. The current study used a regression modeling approach to parse unique and combined contributions of neuropsychological test performance, psychiatric symptoms, and inflammatory cytokine levels in predicting cognitive symptom severity, as measured by questionnaire responses from patient and observer perspectives. Methods: Forty-one patients presenting to a university medical center neurology clinic with cognitive complaints ≥ 4 months after COVID-19 symptom onset were included in the analysis. Results: Although pre-morbid cognitive status was estimated to be at or above-average across participants, nearly 50% performed below expectation on three or more neuropsychological tests. Subjective Cognitive Decline Questionnaire (SCD-Q) ratings were clinically elevated, both from patient (MyCog) and observer (TheirCog) perspectives, yet bivariate relationships with neuropsychological and other measures of PACS symptomatology were non-significant. When combined in regression models, 36% of variance in MyCog score was explained by measures of anxiety, premorbid intelligence, and current neuropsychological test performance. TheirCog scores were explained by a unique set of neuropsychological tests, accounting for 33% of variance cumulatively. Measures of depression, fatigue, and inflammatory cytokines concentrations did not enter either model. Discussion: Taken together, cognitive sequelae of PACS appear to be rooted in changes in brain function that are detectable by objective neuropsychological testing. Although comorbidities associated with PACS can contribute to the experience of cognitive symptoms, we find cognitive symptoms, whether self-reported or observed, to be more directly associated with neuropsychological test performance than ongoing fatigue, psychiatric symptoms, or inflammatory processes. [ABSTRACT FROM AUTHOR] |
| Copyright of Frontiers in Psychiatry is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Βάση Δεδομένων: | Complementary Index |
καταχωρήστε σχόλιο πρώτοι!